



Louisiana Department of Health
Health Plan Advisory 16-35
Revised February 2, 2017

Opioid Edits for Pharmacy Claims

In response to the opioid epidemic, the Louisiana Department of Health (LDH) is implementing targeted opioid quantity limits for pharmacy claims.

On Jan. 10, 2017, opioid quantity limits were implemented in Fee for Service Medicaid for all recipients. Prescribers were alerted to quantity limit proposals before implementation.

Effective March 22, 2017, LDH will implement quantity limits for opioid *naïve* recipients enrolled in Healthy Louisiana managed care organizations (MCO). MCOs are directed to implement the following opioid quantity limits at the Point of Sale (POS) on March 22 for opioid **naïve** recipients (no opioids in the most current 90-day period). Override provisions must be implemented to allow for medically necessary quantities above limits.

To mitigate administrative burden for prescribing providers, LDH is mandating the use of a standardized *Opioid Analgesic Treatment Worksheet* to request overrides and prior authorizations for medically necessary quantities of opioids in excess of the following limits.

Opioid Quantity Limits, Units per 30 day period			
Description	Dosage Form	Units / 30 rolling days	Representative Brand
Hydrocodone Bitartrate	Capsule ER 12 hr	30 units	Zohydro ER®
Hydrocodone/Ibuprofen	Tablet	30 units	Vicoprofen®
Hydrocodone Bitartrate	Tablet ER 24 hr	15 units	Hysingla ER®
Hydrocodone/Acetaminophen	Short Acting Tablet/Capsule	45 units	Lortab®, Vicodin®
Hydromorphone HCl	Short Acting Tablet	45 units	Dilaudid®
Hydromorphone HCl	Tablet ER 24 hr	15 units	Exalgo®
Meperidine	Tablet	45 units	Demerol®
Methadone	Tablet	45 units	

Morphine Sulfate	Tablet	45 units	
Morphine Sulfate	Capsule ER 24 hr	15 units	Avinza®
Morphine Sulfate	Capsule SR Pellet, Tablet SA	30 units	Kadian®, MS Contin®
Morphine Sulfate/Naltrexone	Capsule SR Pellet	30 units	Embeda®
Oxycodone HCl, Oxycodone, Oxycodone/Acetaminophen	Tablet SR 12 hr Capsule ER 12 hr Tablet ER 12 hr	30 units	Oxycontin®, Xtampza ER®, Xartemis XR®
Oxycodone HCl, Oxycodone/Acetaminophen, Oxycodone/Aspirin	Tablet/Capsule	45 units	Roxicodone®, Endocet®, Percocet®, Roxicet®
Oxycodone/Ibuprofen	Tablet	14 units	
Oxymorphone HCl	Tablet	45 units	Opana®
Oxymorphone HCl	Tablet SR 12 hr	30 units	Opana ER®
Tapentadol	Tablet	45 units	Nucynta®
Tapentadol	Tablet ER 12 hr	30 units	Nucynta ER®
Tramadol HCl	Tablet	45 units	Ultram®
Tramadol HCl	Tablet ER 24 hr Capsule ER 24 hr	15 units	Ultram ER® ConZip®
Tramadol/Acetaminophen	Tablet	40 units	Ultracet®

Quantity Limits: Fentanyl Products, Units within a 30 day period

Description	Dosage Form	Route	Units	Limit	Representative Brand
Fentanyl	Patch 12, 25, 50 mcg/hr.	Transdermal	10 units	30 days	Duragesic®
Fentanyl	Patch 75, 100 mcg/hr	Transdermal	20 units	30 days	Duragesic®

Quantity Limits: Only payable for Cancer Diagnosis (C00.*-C98.*)

Fentanyl Citrate Immediate Release	Tablet Sublingual, Lozenge HD, Tab	Sublingual, Buccal	120 units	30 days	Abstral®, Actiq®, Fentora®, Onsolis®
------------------------------------	---------------------------------------	-----------------------	-----------	---------	---

	Effervescence, Film				
--	---------------------	--	--	--	--

Dose Limits: Buprenorphine transdermal		
Description	Units / Limit	Sample Brand Name
Buprenorphine Transdermal Patches	20 mcg/hr (480 mcg/24 hr). Each buprenorphine patch is intended to be worn for 7 days.	Butrans®

Note: Some opioid agents are not indicated for use in opioid naïve recipients. Please consult prescribing information.

In addition to the use of a standard form, LDH is also requiring MCOs to implement Point of Sale overrides to eliminate the need for prescribing providers to submit Prior Authorizations requests for exemption to these quantity limits for select medical conditions. Pharmacy claims for all opioids except fentanyl immediate release should process at Point of Sale when the pharmacist enters appropriate diagnosis codes for the conditions listed below.

Diagnosis Code	Description
C00.*-C96.*	Cancer
Z51.5	Palliative Care
* - any number or letter or combination of UP TO FOUR numbers and letters of an assigned ICD-10-CM diagnosis code	

Provider education on prescribing opioids is encouraged through the MCO Drug Utilization Review process, or any other avenue available. The Department is working on developing online resources for providers.

Please communicate any concerns with this policy to the LDH pharmacy unit.